Abstract
New modalities providing safe and effective treatment of pain, especially prolonged pathological pain, have not appeared despite much effort. In this mini-review/overview we suggest that new paradigms of drug design are required to counter the underlying changes that occur in the nervous system that may elicit chronic pain states. We illustrate this approach with the example of designing, in a single ligand, molecules that have agonist activity at μ and δ opioid receptors and antagonist activities at cholecystokinin (CCK) receptors. Our findings thus far provide evidence in support of this new approach to drug design. We also report on a new biophysical method, plasmon waveguide resonance (PWR) spectroscopy, which can provide new insights into information transduction in G-protein coupled receptors (GPCRs) as illustrated by the δ opioid receptor.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hruby VJ. Designing peptide receptor agonists and antagonists. Nat Rev Drug Discov. 2002;1:847-858.
Ossipov MH, Lai J, Porreca F. Mechanisms of experimental neuropathic pain: Integration from animal models. In: McMahon S, Koltzenburg M, eds. Wall and Melzack’s Textbook of Pain. 5th ed. New York, NY: Elsevier; 2005:929-946.
Ossipov MH, Porreca F. Challenges in the development of novel treatment strategies for neu-ropathic pain. NeuroRx. 2005;2:650-661.
Vera-Portocarrero LP, Zhang ET, Ossipov MH, et al. Descending facilitation from the rostral ventromedial medulla maintains nerve injury-induced central sensitization. Neuroscience. In press.
Ossipov MH, Porreca F. Descending modulation of pain. In: Merskey H, Loeser JD, Dubner R, eds. The Paths of Pain 1975-2005. Seattle, WA: IASP Press; 2005:117-130.
Xie JY, Herman SD, Stiller CO, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci. 2005;25:409-416.
King T, Ossipov MH, Vanderah TW, Porreca F, Lai J. Is paradoxical pain induced by sus-tained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals. 2005;14:194-205.
Heinricher MM, Neubert MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol. 2004;92:1982-1989.
Wilcox GL, Stone LS, Ossipov MH, Lai J, Porreca F. Pharmacology of pain and analgesia. In: Pappagallo M, ed. The Neurologic Basis of Pain. New York, NY: McGraw-Hill; 2004:31-52.
Hruby VJ, Meyer J-P. Chemical synthesis of peptides. In: Hecht SM, ed. Bioorganic Chemistry: Peptides and Proteins. New York, NY: Oxford University Press; 1998:27-64.
Misicka A, Lipkowski AW, Horvath R, et al. Topographical requirements for δ opioid ligands: common structural features of dermenkephalin and deltorphin. Life Sci. 1992;51:1025-1032.
Kramer TH, Davis P, Hruby VJ, Burks TF, Porreca F. In vitro potency, affinity and agonist efficacy of highly selective δ opioid receptor ligands. J Pharmacol Exp Ther. 1993;266:577-584.
Salamon Z, Macleod HA, Tollin G. Coupled plasmon-waveguide resonators: a new spectro-scopic tool for probing proteolipid film structure and properties. Biophys J. 1997;73:2791-2797.
Salamon Z, Tollin G. Plasmon resonance spectroscopy: probing molecular interactions at sur-faces and interfaces. Spectroscopy. 2005;15:161-175.
Tollin G, Salamon Z, Hruby VJ. Techniques: plasmon-waveguide resonance (PWR) spectros-copy as a tool to study ligand-GPCR interactions. Trends Pharmacol Sci. 2003;24:655-659.
Salamon Z, Cowell S, Varga E, Yamamura HI, Hruby VJ, Tollin G. Plasmon resonance stud-ies of agonist/antagonist binding to the human δ-opioid receptor: new structural insights into receptor-ligand interactions. Biophys J. 2000;79:2463-2474.
Alves ID, Salamon Z, Varga E, Yamamura HI, Tollin G, Hruby VJ. Direct observation of G-protein binding to the human δ-opioid receptor using plasmon-waveguide resonance spectros-copy. J Biol Chem. 2003;278:48890-48897.
Slaninová J, Knapp RJ, Wu J, et al. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide. Eur J Pharmacol. 1991;200:195-198.
Mosberg HI, Hurst R, Hruby VJ, et al. Bis-penicillamine enkephalins possess highly improved specificity toward δ opioid receptors. Proc Natl Acad Sci USA. 1983;80:5871-5874.
Hruby VJ, Fang SN, Kramer TH. Analogues of cholecystokinin26-33 selective for B-type CCK receptors possess δ opioid receptor agonist activity in vitro and in vivo: Evidence for similari-ties in CCK-B and δ opioid receptor requirements. In: Hodges RS, Smith JA, eds. Peptides: Chemistry, Structure and Biology. Proceedings of the 13th American Peptide Symposium; June 20-25, 1993; Alberta, Canada. Leiden, The Netherlands: ESCOM Publishers; 1994: 669-671.
Nikiforovich GV, Hruby VJ, Prakash O, Gehrig CA. Topographical requirements for δ-selec-tive opioid peptides. Biopolymers. 1991;31:941-955.
Hruby VJ, Fang SN, Knapp R, Kazmierski WM, Lui GK, Yamamura HI. Cholecystokinin analogues with high affinity and selectivity for brain membrane receptors. Int J Pept Protein Res. 1990;35:566-573.
Hruby VJ. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sci. 1982;31:189-199. 494V.J. Hruby et al.
Hruby VJ, Al-Obeidi F, Kazmierski WM. Emerging approaches in the molecular design of receptor selective peptide ligands: conformational, topographical and dynamic considerations. Biochem J. 1990;268:249-262.
Bartosz-Bechowski H, Davis P, Slaninova J, et al. Cyclic enkephalin analogues that are hybrids of DPDPE-related peptides and Met-enkephalin-Arg-Gly-Leu: prohormone analogues that retain good potency and selectivity for δ opioid receptors. J Pept Res. 1999;53:329-336.
Hruby VJ, Bartosz-Bechowski H, Davis P, et al. Cyclic enkephalin analogues with excep-tional potency and selectivity for δ-opioid receptors. J Med Chem. 1997;40:3957-3962.
Alves ID, Cowell SM, Salamon Z, Devanathan S, Tollin G, Hruby VJ. Different structural states of the proteolipid membrane are produced by ligand binding to the human δ-opioid receptor as shown by plasmon-waveguide resonance spectroscopy. Mol Pharmacol. 2004;65:1248-1257.
Hosohata Y, Varga EV, Stropova D, et al. Mutation W284L of the human δ opioid receptor reveals agonist specific conformational mechanisms of G-protein activation. Life Sci. 2001;68:2233-2242.
Alves ID, Salamon Z, Varga E, Yamamura HI, Tollin G, Hruby VJ. Direct observation of G-protein binding to the human δ-opioid receptor using plasmon-waveguide resonance spectros-copy. J Biol Chem. 2003;278:48890-48897.
Alves ID, Ciano KA, Boguslavsky V, et al. Selectivity, cooperativity, and reciprocity in the interactions between the δ-opioid receptor, its ligands, and G-proteins. J Biol Chem. 2004;279:44673-44682.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Hruby, V.J. et al. (2008). New Paradigms and Tools in Drug Design for Pain and Addiction. In: Rapaka, R.S., Sadée, W. (eds) Drug Addiction. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76678-2_28
Download citation
DOI: https://doi.org/10.1007/978-0-387-76678-2_28
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-76677-5
Online ISBN: 978-0-387-76678-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
